DOCOV: Description of Ophthalmologic Injuries in Intensive Care During the SARS-CoV2 Epidemic - COVID19
Study Details
Study Description
Brief Summary
The management of patients with SARS-CoV2 in respiratory distress can expose to corneal or retinal lesions induced by the stay in intensive care.
Examination by ophthalmologists would make it possible to detect the most of the ophthalmologic problems known in intensive care and to provide an early, preventive or curative therapeutic response when possible, in order to avoid irreversible visual loss.
The object of the research is to assess the presence and the importance of surface ophthalmologic lesions, the presence and the importance of retinal or optic nerve lesions, in order to improve the monitoring and primary prevention of this population
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: Ophthalmologic exam
|
Procedure: Ophthalmologic exam
Direct exam and Slit lamp exam Shirmer test Retinophotography At inclusion, day 7, day 14 and discharge from hospital
|
Outcome Measures
Primary Outcome Measures
- Describe ophthalmologic damage to the cornea with direct exam at day 0 [Day 0]
Direct exam
- Describe ophthalmologic damage to the cornea with direct exam at day 7 [Day 7]
Direct exam
- Describe ophthalmologic damage to the cornea with direct exam at day 14 [Day 14]
Direct exam
- Describe ophthalmologic damage to the cornea with direct exam at discharge of hospital [Discharge of hospital, up to 3 months]
Direct exam
- Describe ophthalmologic damage to the cornea with slit lamp exam at day 0 [Day 0]
Slit lamp exam
- Describe ophthalmologic damage to the cornea with slit lamp exam at day 7 [Day 7]
Slit lamp exam
- Describe ophthalmologic damage to the cornea with slit lamp exam at day 14 [Day 14]
Slit lamp exam
- Describe ophthalmologic damage to the cornea with slit lamp exam at discharge of hospital [Discharge of hospital, up to 3 months]
Slit lamp exam
- Describe tear film anomalies at day 0 [Day 0]
Shirmer test
- Describe tear film anomalies at day 7 [Day 7]
Shirmer test
- Describe tear film anomalies at day 14 [Day 14]
Shirmer test
- Describe tear film anomalies at discharge of hospital [Discharge of hospital, up to 3 months]
Shirmer test
- Describe ophthalmologic damage to the retina at day 0 [Day 0]
Retinophotography
- Describe ophthalmologic damage to the retina at day 7 [Day 7]
Retinophotography
- Describe ophthalmologic damage to the retina at day 14 [Day 14]
Retinophotography
- Describe ophthalmologic damage to the retina at discharge of hospital [Discharge of hospital, up to 3 months]
Retinophotography
- Describe ophthalmologic damage to the optic nerve at day 0 [Day 0]
Retinophotography
- Describe ophthalmologic damage to the optic nerve at day 7 [Day 7]
Retinophotography
- Describe ophthalmologic damage to the optic nerve at day 14 [Day 14]
Retinophotography
- Describe ophthalmologic damage to the optic nerve at discharge of hospital [Discharge of hospital, up to 3 months]
Retinophotography
Eligibility Criteria
Criteria
Inclusion Criteria:
-
patient SARS-CoV2 positive (RT-PCR or chest scanner)
-
hospitalized in intensive care
Exclusion Criteria:
- traumatic lesion of the face or any other condition preventing any ophthalmological evaluation
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Fondation Adolphe de Rothschild | Paris | France | 75019 |
Sponsors and Collaborators
- Fondation Ophtalmologique Adolphe de Rothschild
Investigators
- Principal Investigator: Jean Michel DEVYS, MD, Fondation Adolphe de Rothschild
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- JDS_2020_13